Latest Investment News

Queste Communications Ltd reported a modest profit for FY25, with consolidated results impacted by investment portfolio losses and strategic asset reclassifications. The company maintained a cautious stance, suspending dividends and executive salaries to manage overheads.

Gumtree Australia Markets Limited reports a transformational FY25 marked by a $6.8 million Capital Markets division sale, a near doubling of EBITDA, and promising expansions in transactional services and partnerships.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

Orion Equities reported a $1.33 million net profit for FY25, down 56% from the prior year, impacted by unrealised losses on key investments and a significant tax benefit reversal. The company’s portfolio remains anchored by stakes in Bentley Capital and Strike Resources.

Pentanet Limited has achieved its first full-year positive EBITDA of $1.4 million in FY25, driven by strong growth in its telecommunications and gaming segments, alongside strategic 5G network expansion and technology upgrades.

Swift Networks Group reported a 3.5% revenue decline in FY25 and a near doubling of losses, while raising $2.3 million and extending loan terms amid contract uncertainties.

Pentanet has achieved its first full-year positive EBITDA of $1.4 million in FY25, driven by strong growth in 5G subscribers and a profitable gaming segment. The company’s strategic focus on capital-efficient 5G expansion and gaming platform optimisation signals a new phase of growth.

Pentanet Limited has reported its first-ever positive EBITDA of $1.4 million for FY25, alongside an 8% revenue increase and a significant expansion of its 5G Fixed Wireless network covering a quarter of its tower footprint.

Gold Road Resources reports a robust half-year profit surge driven by higher gold prices and sales, while advancing a proposed acquisition by Gold Fields with a shareholder vote set for September.

WhiteHawk Limited reports an 8.6% revenue increase and a 26% reduction in net loss for H1 2025, alongside new US government contracts and a $1.56 million capital raise.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Atlas Pearls reported increased pearl harvest and sales volumes for FY25, driving revenue growth to $44.3 million, though profits declined compared to the previous year. The company declared a fully franked final dividend, underscoring its solid financial footing.